Abstract
The effect of a high dose oral cholecalciferol repletion strategy in Vitamin D insufficient adults with CF is still unknown. Therefore, we assessed the effectiveness of our current approach, giving oral vitamin D3 supplementation at a dose of 10,000IU from Monday to Friday for a total of 50,000IU D3 weekly in vitamin D insufficient adult with CF. We performed a retrospective chart review of all 59 adult CF patients between the ages of 17 and 64 years routinely followed at the CF Adult Program of Winnipeg Health Sciences Centre. Through consultation with the endocrinologist, our clinic vitamin D repletion protocol for treating CF adult patients who have serum 25-hydroxyvitamin D (25-OHD)<30ng/ml (<75nmol/L) was to prescribe vitamin D3 10,000IU orally from Monday to Friday (or the weekly equivalent of 50,000IU) for 12 weeks in addition to their regular CF vitamin that supplied from 800 to 2000IU vitamin D3 daily. Cholecalciferol was conveniently administered orally as either one capsule (oil-based) 10,000IU or one tablet (powder-based) 10,000IU. All patients were instructed to obtain follow-up serum 25-OHD levels post completion of treatment. Of the 59 adult patients at our CF Clinic, 35 patients (59%) had below optimal serum 25-OHD levels. Of the 35 patients identified, 10 patients with insufficient serum 25-OHD levels between 10 and 30ng/ml (25-75nmol/L) fulfilled the inclusion criteria. A significant increase in serum 25-OHD levels was observed (P<0.01) from mean value of 21.6±5.9ng/ml (54.1±14.8nmol/L) at baseline to 31.7±9.1ng/ml (79.3±22.8nmol/L)≥2 months post intervention. The current treatment approach was successful in treating Vitamin D insufficiency in 70% of the patients with low 25-OHD levels. The results of this study demonstrate that a large number of adults attending Winnipeg Health Sciences Centre CF Clinic have serum 25-OHD levels below 30ng/ml (75nmol/L). This supports the need for dedicated and individualized approach to manage this condition. High dose therapy of vitamin D3, although a more aggressive treatment approach, may result in achieving optimal levels of serum 25-OHD in adults with CF.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.